|
The purpose of this committee is to provide advice and oversight of the NCI’s RAID Program and to assist the Developmental Therapeutics Program in the translation to the clinic of novel anticancer therapeutic interventions, either synthetic, natural product, or biologic that have been approved for development. In particular, academic institutions need a bridge between discovery and clinical testing, so that efficient translation of promising discoveries may take place even in the absence of development capacity or clinical expertise in the institution where the discovery was made and the NCI’s RAID Program helps bridge this gap. This committee should also foster greater interactions with industry, academia, government, etc. to enhance the drug development process.
This committee will also provide advice on policies, procedures and programs that will enhance the pre-clinical discovery and development of small molecules and biologics. Particular emphasis will be to provide oversight of the NCI Rapid Access to Intervention Development (RAID) program. The goal is to optimize the functionality and output of the NCI’s RAID program and to explore the potential contribution of current and future drug discovery and development practices to optimize strategies to preempt cancer at various stages.
|
